496 related articles for article (PubMed ID: 12769339)
41. Chemotherapy is effective as early treatment for primary central nervous system lymphoma.
Boiardi A; Silvani A; Pozzi A; Fariselli L; Broggi G; Salmaggi A
J Neurol; 1999 Jan; 246(1):31-7. PubMed ID: 9987711
[TBL] [Abstract][Full Text] [Related]
42. Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma.
Soussain C; Suzan F; Hoang-Xuan K; Cassoux N; Levy V; Azar N; Belanger C; Achour E; Ribrag V; Gerber S; Delattre JY; Leblond V
J Clin Oncol; 2001 Feb; 19(3):742-9. PubMed ID: 11157026
[TBL] [Abstract][Full Text] [Related]
43. Intensive chemotherapy with thiotepa, busulfan and cyclophosphamide and hematopoietic stem cell rescue in relapsed or refractory primary central nervous system lymphoma and intraocular lymphoma: a retrospective study of 79 cases.
Soussain C; Choquet S; Fourme E; Delgadillo D; Bouabdallah K; Ghesquières H; Damaj G; Dupriez B; Vargaftig J; Gonzalez A; Houillier C; Taillandier L; Hoang-Xuan K; Leblond V
Haematologica; 2012 Nov; 97(11):1751-6. PubMed ID: 22581000
[TBL] [Abstract][Full Text] [Related]
44. Chemotherapy without radiation therapy as initial treatment for primary CNS lymphoma in older patients.
Freilich RJ; Delattre JY; Monjour A; DeAngelis LM
Neurology; 1996 Feb; 46(2):435-9. PubMed ID: 8614508
[TBL] [Abstract][Full Text] [Related]
45. (R)-GEMOX chemotherapy for unfit patients with refractory or recurrent primary central nervous system lymphoma: a LOC study.
Collignon A; Houillier C; Ahle G; Chinot O; Choquet S; Schmitt A; Agape P; Soussain C; Hoang-Xuan K; Tabouret E
Ann Hematol; 2019 Apr; 98(4):915-922. PubMed ID: 30535802
[TBL] [Abstract][Full Text] [Related]
46. A study of rituximab and ifosfamide, carboplatin, and etoposide chemotherapy in children with recurrent/refractory B-cell (CD20+) non-Hodgkin lymphoma and mature B-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group.
Griffin TC; Weitzman S; Weinstein H; Chang M; Cairo M; Hutchison R; Shiramizu B; Wiley J; Woods D; Barnich M; Gross TG;
Pediatr Blood Cancer; 2009 Feb; 52(2):177-81. PubMed ID: 18816698
[TBL] [Abstract][Full Text] [Related]
47. A successful treatment of relapsed primary CNS lymphoma patient with intraventricular rituximab followed by high-dose chemotherapy with autologous stem cell rescue.
Hong SJ; Kim JS; Chang JH; Kim KM; Kim SJ; Lee HW; Cheong JW; Lee ST; Min YH
Yonsei Med J; 2009 Apr; 50(2):280-3. PubMed ID: 19430564
[TBL] [Abstract][Full Text] [Related]
48. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma.
Witzig TE; Flinn IW; Gordon LI; Emmanouilides C; Czuczman MS; Saleh MN; Cripe L; Wiseman G; Olejnik T; Multani PS; White CA
J Clin Oncol; 2002 Aug; 20(15):3262-9. PubMed ID: 12149300
[TBL] [Abstract][Full Text] [Related]
49. A salvage chemotherapy of R-P-IMVP16/CBDCA consisting of rituximab, methylprednisolone, ifosfamide, methotrexate, etoposide, and carboplatin for patients with diffuse large B cell lymphoma who had previously received R-CHOP therapy as first-line chemotherapy.
Matsumoto T; Hara T; Shibata Y; Nakamura N; Nakamura H; Ninomiya S; Kitagawa J; Kanemura N; Goto N; Kito Y; Kasahara S; Yamada T; Sawada M; Miyazaki T; Takami T; Takeuchi T; Moriwaki H; Tsurumi H
Hematol Oncol; 2017 Sep; 35(3):288-295. PubMed ID: 26999778
[TBL] [Abstract][Full Text] [Related]
50. Utility of post-therapy brain surveillance imaging in the detection of primary central nervous system lymphoma relapse.
Fossard G; Ferlay C; Nicolas-Virelizier E; Rey P; Ducray F; Jouanneau E; Faurie P; Belhabri A; Sunyack MP; Chassagne-Clément C; Thiesse P; Sebban C; Biron P; Blay JY; Ghesquières H
Eur J Cancer; 2017 Feb; 72():12-19. PubMed ID: 28012348
[TBL] [Abstract][Full Text] [Related]
51. Blood-brain barrier disruption and intra-arterial methotrexate-based therapy for newly diagnosed primary CNS lymphoma: a multi-institutional experience.
Angelov L; Doolittle ND; Kraemer DF; Siegal T; Barnett GH; Peereboom DM; Stevens G; McGregor J; Jahnke K; Lacy CA; Hedrick NA; Shalom E; Ference S; Bell S; Sorenson L; Tyson RM; Haluska M; Neuwelt EA
J Clin Oncol; 2009 Jul; 27(21):3503-9. PubMed ID: 19451444
[TBL] [Abstract][Full Text] [Related]
52. Relapse of primary central nervous system lymphoma: clinical features, outcome and prognostic factors.
Jahnke K; Thiel E; Martus P; Herrlinger U; Weller M; Fischer L; Korfel A;
J Neurooncol; 2006 Nov; 80(2):159-65. PubMed ID: 16699873
[TBL] [Abstract][Full Text] [Related]
53. A single institutional retrospective evaluation for younger patients with primary central nervous lymphomas on a modified R-MPV regimen followed by radiotherapy and high dose cytarabine.
Hattori K; Sakata-Yanagimoto M; Okoshi Y; Kato T; Kurita N; Yokoyama Y; Obara N; Takano S; Ishikawa E; Yamamoto T; Matsumura A; Hasegawa Y; Chiba S
J Clin Exp Hematop; 2017 Oct; 57(2):41-46. PubMed ID: 28781291
[TBL] [Abstract][Full Text] [Related]
54. Enhanced chemotherapy delivery by intraarterial infusion and blood-brain barrier disruption in malignant brain tumors: the Sherbrooke experience.
Fortin D; Desjardins A; Benko A; Niyonsega T; Boudrias M
Cancer; 2005 Jun; 103(12):2606-15. PubMed ID: 15880378
[TBL] [Abstract][Full Text] [Related]
55. Characteristics and Outcomes of Primary Central Nervous System Lymphoma: A Retrospective Study of 91 Cases in a Chinese Population.
Mao C; Chen F; Li Y; Jiang X; Liu S; Guo H; Huang L; Wei X; Liang Z; Li W; Tang K
World Neurosurg; 2019 Mar; 123():e15-e24. PubMed ID: 30326304
[TBL] [Abstract][Full Text] [Related]
56. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma.
Witzig TE; White CA; Wiseman GA; Gordon LI; Emmanouilides C; Raubitschek A; Janakiraman N; Gutheil J; Schilder RJ; Spies S; Silverman DH; Parker E; Grillo-López AJ
J Clin Oncol; 1999 Dec; 17(12):3793-803. PubMed ID: 10577851
[TBL] [Abstract][Full Text] [Related]
57. Rituximab, methotrexate, procarbazine, vincristine and intensified cytarabine consolidation for primary central nervous system lymphoma (PCNSL) in the elderly: a LOC network study.
Houillier C; Ghesquières H; Chabrot C; Soussain C; Ahle G; Choquet S; Nicolas-Virelizier E; Bay JO; Vargaftig J; Gaultier C; Touitou V; Martin-Duverneuil N; Cassoux N; Le Garff-Tavernier M; Costopoulos M; Faurie P; Hoang-Xuan K
J Neurooncol; 2017 Jun; 133(2):315-320. PubMed ID: 28432587
[TBL] [Abstract][Full Text] [Related]
58. Subsequent chemotherapy regimens are well tolerated after radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for non-Hodgkin's lymphoma.
Ansell SM; Ristow KM; Habermann TM; Wiseman GA; Witzig TE
J Clin Oncol; 2002 Sep; 20(18):3885-90. PubMed ID: 12228209
[TBL] [Abstract][Full Text] [Related]
59. Upfront consolidation combining yttrium-90 ibritumomab tiuxetan and high-dose therapy with stem cell transplantation in poor-risk patients with diffuse large B cell lymphoma.
Fruchart C; Tilly H; Morschhauser F; Ghesquières H; Bouteloup M; Fermé C; Van Den Neste E; Bordessoule D; Bouabdallah R; Delmer A; Casasnovas RO; Ysebaert L; Ciappuccini R; Briere J; Gisselbrecht C
Biol Blood Marrow Transplant; 2014 Dec; 20(12):1905-11. PubMed ID: 25072780
[TBL] [Abstract][Full Text] [Related]
60. High-dose thiotepa, busulfan, cyclophosphamide and ASCT without whole-brain radiotherapy for poor prognosis primary CNS lymphoma.
Cheng T; Forsyth P; Chaudhry A; Morris D; Glück S; Russell JA; Stewart DA
Bone Marrow Transplant; 2003 Apr; 31(8):679-85. PubMed ID: 12692608
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]